RxDoctor Payments Data

Kesha Zaveri

Family Medicine · Sugar Land, TXNPI 1457763021

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 27.3% of the total. 2025 is the largest year on record at $334, 8.2 times the $41 reported in 2019. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.

$550in general payments, 2019–2025

Across 20 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$150
  • Novo Nordisk$106
  • Pulmonx Corporation$63
  • Hologic Sales And Service, LLC$33
  • Inspire Medical Systems, Inc.$30
  • Lilly USA, LLC$24
  • plus $145 from 9 others

What the payments were for

  • Food & beverage$550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$550 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$23,161
Medicare patients
51
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$22,344
TrulicityDulaglutide11$14,762
Atorvastatin Calcium172$1,579
Gabapentin48$917
Lisinopril89$662
Amlodipine Besylate75$507
Alendronate Sodium58$478
Metformin Hcl47$394
Olmesartan Medoxomil11$384
Losartan Potassium70$384
Simvastatin26$377
Pantoprazole Sodium32$322
Rosuvastatin Calcium23$319
Albuterol Sulfate HfaAlbuterol Sulfate11$306
Pravastatin Sodium32$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$106$22,34417 claims
Lilly USA, LLCTrulicity$24$14,76211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →